Vaxart is a clinical-stage biotech developing oral tablet vaccines, but its digital presence reveals a company struggling to convert funding into market traction. With a global rank of #4.4M and 100% traffic from undefined sources, the gap between their scientific ambition and digital execution is stark.

"A company with $4.2M in revenue and 149 employees should rank higher than #4.4M globally—unless investors aren't searching."

Their tech stack—WordPress with Tailwind CSS and Cloudflare—is adequate but uninspired for a clinical-stage biotech. The lack of Trustpilot reviews isn't surprising for a B2B/pharma company, but the absence of backlink data suggests minimal digital PR or scientific content marketing. For a company developing oral vaccines for norovirus (5,230 monthly searches) and COVID-19, they're invisible in the scientific community's digital conversation.

• Oral vaccine platform targeting norovirus, COVID-19, and influenza
• Clinical-stage with $52.7M funding but only $4.2M revenue
• Strong executive team with pharma regulatory experience
• Digital presence misaligned with scientific ambitions
• Investor-focused search traffic instead of patient/clinician focus